Surgery Partners (NASDAQ:SGRY) Posts Earnings Results, Beats Expectations By $0.01 EPS

Surgery Partners (NASDAQ:SGRY) released its quarterly earnings results on Monday. The company reported $0.39 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.01, Zacks reports. Surgery Partners had a negative net margin of 2.03% and a positive return on equity of 2.85%. Surgery Partners updated its FY 2025 guidance to EPS.

Surgery Partners Stock Down 2.2 %

Shares of NASDAQ:SGRY opened at $24.08 on Monday. The company has a fifty day moving average of $23.04 and a 200-day moving average of $26.45. The company has a market capitalization of $3.06 billion, a PE ratio of -50.17, a price-to-earnings-growth ratio of 19.21 and a beta of 2.60. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.66 and a current ratio of 1.80. Surgery Partners has a 52-week low of $19.50 and a 52-week high of $33.97.

Insider Transactions at Surgery Partners

In related news, insider Harrison R. Bane sold 56,315 shares of the firm’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $25.64, for a total transaction of $1,443,916.60. Following the completion of the transaction, the insider now directly owns 107,037 shares of the company’s stock, valued at $2,744,428.68. This trade represents a 34.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO David T. Doherty sold 13,641 shares of the firm’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $25.61, for a total value of $349,346.01. Following the transaction, the chief financial officer now directly owns 108,862 shares of the company’s stock, valued at approximately $2,787,955.82. This represents a 11.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 96,733 shares of company stock worth $2,480,106. Corporate insiders own 2.30% of the company’s stock.

Analyst Upgrades and Downgrades

SGRY has been the subject of a number of analyst reports. Bank of America initiated coverage on shares of Surgery Partners in a research report on Monday, December 16th. They issued a “buy” rating and a $30.00 price target for the company. Macquarie reiterated an “outperform” rating and issued a $34.00 price target on shares of Surgery Partners in a research report on Tuesday, November 19th. JPMorgan Chase & Co. lowered their price objective on shares of Surgery Partners from $38.00 to $28.00 and set a “neutral” rating for the company in a research report on Tuesday, December 3rd. Finally, Royal Bank of Canada lowered their price objective on shares of Surgery Partners from $49.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Surgery Partners has an average rating of “Moderate Buy” and a consensus target price of $36.56.

Surgery Partners Company Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.